Axsome Thera (AXSM)
$50.59 2.96 (5.53%)
14:55 EDT AXSM Stock Quote Delayed 20 Minutes
Previous Close $53.55
Market Cap 1.30B
PE Ratio -48.18
Volume (Avg. Vol.) 1.03M
Day's Range 49.36 - 54.76
52-Week Range 13.25 - 109.94
Dividend & Yield N/A (N/A)
AXSM Stock Predictions, Articles, and Axsome Thera News
- From InvestorPlace
- From the Web
By Ian Cooper
Some of the biggest catalysts for future growth in drug stocks include the millions of retiring baby boomers, and new innovative treatments for a variety of medical issues.
Axsome Therapeutics (AXSM) news for Monday about results from the company's Phase 3 Trial of AXS-05 has AXSM stock rocketing higher.
With FDA Breakthrough Therapy designations and robust drug pipelines, these biotech companies are all stocks to buy for 2020.
These 10 stocks, including SHOP stock, have been among the best stocks in the market over the past year. Where do they go from here?
No longer a penny stock, Axsome Therapeutics (AXSM) surged past $8 a share on news that its AXS-05 treatment affected a 17.2-point drop in patients on the Montgomery-Asbert Depression Rating Scale. But is it a buy?
Axsome Therapeutics (AXSM) stock was flying high on Monday following some good AXSM news about a recent Phase 2 drug trial.
From Market News Video
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Scientific Games Corp (SGMS), where a total of 14,425 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 47.2% of SGMS's average daily trading volume over the past month of 3.1 million shares..
From Analyst Ratings
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $200.00. The company’s shares closed last Friday at $55.02. According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.7% and a 23.0% success rate.
Navellier RatingsPowered by Portfolio Grader